• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
North American Drug Delivery Technologies Market – Forecasts To 2017 - Product Image

North American Drug Delivery Technologies Market – Forecasts To 2017

  • Published: July 2013
  • Region: North America, United States
  • 267 Pages
  • Markets and Markets

FEATURED COMPANIES

  • Aptalis Pharma, Inc
  • Baxter International, Inc
  • Catalent Pharma Solutions
  • Cima Labs
  • Johnson & Johnson, Inc
  • M Company
  • MORE

'North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) – Forecasts To 2017'

This research report categorizes and analyzes the North American Drug Delivery Technologies market on the basis of routes of administration. These markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (U.S and Canada), to provide in-depth information on the North American market scenario.

The patent expiry of major blockbuster drugs is a prime concern for pharmaceutical companies, as developing a new chemical entity (NCE) is more expensive and time consuming than a novel drug delivery technology. Therefore, in recent years, several pharmaceutical companies have employed drug delivery technology as a life cycle management tool for some of their blockbuster drugs, the patents for which are set to expire in the near future.

The North American drug READ MORE >

1 Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary

3 Market Overview
3.1 Introduction
3.2 Market Segmentation
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Patent Cliff And Increased Competition To Increase Adoption Rate
3.3.1.2 Improving Patient Compliance And Acceptability, An Impetus To The Drug Delivery Systems Market
3.3.1.3 Increasing Focus On Pediatric And Geriatric Patients To Boost The Growth
3.3.1.4 Increasing Incidence Of Chronic Diseases In North America To Enhance Demand
3.3.2 Restraints
3.3.2.1 Drug Failures And Recalls Mar Market Growth
3.3.2.2 Technical Barriers Restrict Growth
3.3.3 Opportunities
3.3.3.1 Collaborations Between Pharmaceutical Companies And Drug Delivery Firms
3.3.3.2 Self-Administration And Home Care Drug Delivery Devices
3.3.3.3 Expanding Therapeutic Applications Of Drug Delivery Technologies
3.3.4 Targeted Drug Delivery
3.3.4.1 Passive Systems Contribute 60% To The Targeted Drug Delivery Market
3.3.4.2 Active Targeted Drug Delivery Has Major Applications In Cancer Therapy
3.3.4.3 Companies Focus On Novel Targeted Drug Delivery
3.3.5 Burning Issues
3.3.5.1 Striking Right Partnerships
3.3.5.2 Improving The Bioavailability Of Drugs
3.4 Regulatory Environment
3.4.1 Stringent Regulations For Pharmaceutical Drugs In North America
3.4.1.1 The Approval Process Is Complex, Time-Consuming, And Expensive
3.4.2 Effect Of The U.S. Healthcare Reforms On The Drug Delivery Industry
3.4.2.1 Drug Delivery Companies To Benefit From The Affordable Care Act (Aca) Reform In The Long Run
3.4.3 Regulations Related To The Approval Of Controlled Release Drugs
3.5 Porter’s Five Forces Analysis
3.5.1 Threat Of New Entrants
3.5.2 Threat Of Substitutes
3.5.3 Competitor’s Rivalry
3.5.4 Bargaining Power Of Suppliers
3.5.5 Bargaining Power Of Buyers
3.6 Value Chain Analysis
3.7 Market Share Analysis
3.7.1 Pulmonary Drug Delivery
3.7.1.1 U.S.
3.7.1.2 Canada
3.7.2 Transdermal Drug Delivery
3.7.2.1 U.S.
3.7.2.2 Canada
3.7.3 Inectable Drug Delivery Devices
3.7.3.1 U.S.
3.7.3.2 Canada
3.7.4 Implantable Drug Delivery
3.7.4.1 U.S.
3.7.4.2 Canada
3.7.5 Other Drug Delivery Segments

4 North America Drug Delivery Market, By Technology
4.1 Introduction
4.1.1 Drug Delivery Market Witnessing Technological Advancements
4.2 Opportunity Matrix
4.3 Oral Drug Delivery
4.3.1 Reformulation Strategies & Establishing In-House Capabilities Help In Significant Growth
4.3.2 Controlled Release
4.3.3 Orodispersible Tablets (ODT) And Taste Masking
4.3.4 Others
4.4 Pulmonary Drug Delivery
4.4.1 Therapeutic Applications Of Pulmonary Delivery
4.4.1.1 Application Of Pulmonary Delivery For Non-Respiratory Therapies Is A Growing Opportunity
4.4.2 Metered Dose Inhalers (MDI)
4.4.3 Dry Powder Inhalers (DPI)
4.4.4 Nebulizers
4.5 Transdermal Drug Delivery
4.5.1 Passive Transdermal Drug Delivery
4.5.1.1 Matrix System
4.5.1.2 Reservoir System
4.5.2 Active Transdermal Drug Delivery
4.5.2.1 Microporation
4.5.2.2 Iontophoresis
4.5.2.3 Others
4.6 Injectable Drug Delivery
4.6.1 Injectable Drug Delivery Market Witnessing Developments Related To Product Improvement
4.6.2 Conventional Injectable Drug Delivery Devices
4.6.2.1 Low Manufacturing Cost And Affordable Prices: Key Driver For Conventional Injection Devices
4.6.2.2 Fillable
4.6.2.3 Prefilled
4.6.3 Self-Injection Devices
4.6.3.1 Self-Injection Devices Reduce Overall Treatment Cost
4.6.3.2 Pen Injectors
4.6.3.3 Needle-Free Injectors
4.6.3.4 Auto Injectors
4.6.4 Others
4.7 Ocular Drug Delivery
4.7.1 Eye Drops
4.7.2 Ointments And Gels
4.7.3 Others
4.8 Nasal Drug Delivery
4.8.1 Nasal Drug Delivery Preferred For Locally Acting Drugs And Delivery Of Vaccines
4.8.2 Nasal Sprays
4.8.3 Nasal Inhalers
4.8.4 Nasal Drops
4.8.5 Others
4.9 Topical Drug Delivery
4.9.1 Topical Delivery Majorly Adopted For Dermatology Drugs
4.9.2 Semi-Solid Formulations
4.9.3 Liquid Formulations
4.9.4 Solid Formulations
4.10 Implantable Drug Delivery
4.10.1 Drug- Eluting Stents
4.10.2 Implantable Infusion Pumps
4.10.2.1 Implantable Infusion Pumps Largely Used For Therapies Of Chronic Ailments
4.10.3 Contraceptive Implants
4.10.4 Intravitreal Implants
4.10.5 Brachytherapy Seeds
4.11 Transmucosal Drug Delivery
4.11.1 Oral (Buccal And Sublingual)
4.11.2 Others (Rectal, Vaginal)

5 Geographic Analysis
5.1 Introduction
5.2 United States
5.2.1 Well-Established U.S. Pharmaceutical Industry Drives The Drug Delivery Market
5.2.2 Favorable Changes In The Fda To Accelerate Drug Review And Approval Processes
5.2.3 U.S. Healthcare Reforms Will Impact The Drug Delivery Market
5.3 Canada
5.3.1 Insurance Coverage Favoring The Growth Of Canadian Drug Delivery Technology Market
5.3.2 Rise In Number Of Approvals And Agreements In The Canada Drug Delivery Market

6 Competitive Landscape
6.1 Introduction
6.1.1 Mergers & Acquisitions And Agreements & Collaborations Were The Key Strategies Adopted By Players
6.2 Mergers & Acquisitions
6.3 Agreements, Collaborations, Joint Ventures & Partnerships
6.4 New Product Launch
6.5 Other Developments

7 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)*
7.1 3M Company
7.2 Aptalis Pharma, Inc.
7.3 Baxter International, Inc.
7.4 Becton, Dickinson And Company
7.5 Catalent Pharma Solutions
7.6 Cima Labs
7.7 Endo Health Solutions, Inc.
7.8 Johnson & Johnson, Inc.
7.9 Nektar Therapeutics, Inc.
7.10 Optinose As
7.11 Psivida Corporation
7.12 The Dow Chemical Company
7.13 Valeant Pharmaceuticals

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

List of Tables (95 Tables)

Table 1 North America Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 2 Key Drug Delivery Technology Providers & Marketer Companies
Table 3 North American Drug Delivery Market, By Route Of Administration, 2010 – 2017
Table 4 North American Oral Drug Delivery Market, By Technology, 2010 – 2017 ($Million)
Table 5 North American Oral Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 6 Controlled Release Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 7 Odt & Taste-Masking Market, By Country, 2010 – 2017 ($Million)
Table 8 Other Oral Drug Delivery Technologies Market, By Country, 2010 – 2017 ($Million)
Table 9 North American Pulmonary Drug Delivery Market, By Device Type, 2010 – 2017 ($Million)
Table 10 North American Pulmonary Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 11 Comparative Overview Of Pulmonary Drug Delivery Devices
Table 12 Metered Dose Inhalation Market, By Country, 2010 – 2017 ($Million)
Table 13 Dry Powder Inhalation Market, By Country, 2010 – 2017 ($Million)
Table 14 Nebulizers Market, By Country, 2010 – 2017 ($Million)
Table 15 North American Transdermal Drug Delivery Market, By Mode Of Delivery, 2010 – 2017 ($Million)
Table 16 North American Transdermal Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 17 Passive Transdermal Drug Delivery Market, By Technology, 2010 – 2017 ($Million)
Table 18 Passive Transdermal Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 19 Active Transdermal Drug Delivery Market, By Technology, 2010 – 2017 ($Million)
Table 20 Active Transdermal Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 21 North American Injectable Drug Delivery Market, By Product Type, 2010 – 2017 ($Billion)
Table 22 North American Injectable Drug Delivery Market, By Country, 2010 – 2017 ($Billion)
Table 23 Conventional Injection Devices Market, By Product, 2010 – 2017 ($Billion)
Table 24 Conventional Injection Devices Market, By Country, 2010 – 2017 ($Billion)
Table 25 Self-Injection Devices Market, By Product, 2010 – 2017 ($Million)
Table 26 Self-Injection Devices Market, By Country, 2010 – 2017 ($Million)
Table 27 Other Injectors Market, By Country, 2010 – 2017 ($Million)
Table 28 North American Ocular Drug Delivery Market, By Formulation, 2010 – 2017 ($Million)
Table 29 North American Ocular Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 30 Eye Drop Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 31 Ointment & Gel Delivery Market, By Country, 2010 – 2017 ($Million)
Table 32 Other Ocular Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 33 North American Nasal Drug Delivery Market, By Formulation, 2010 – 2017 ($Million)
Table 34 North American Nasal Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 35 Nasal Spray Market, By Country, 2010 – 2017 ($Million)
Table 36 Nasal Inhaler Market, By Country, 2010 – 2017 ($Million)
Table 37 Nasal Drops Market, By Country, 2010 – 2017 ($Million)
Table 38 Other Nasal Delivery Formulations Market, By Country, 2010 – 2017 ($Million)
Table 39 North American Topical Drug Delivery Market, By Formulation, 2010 – 2017 ($Million)
Table 40 North American Topical Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 41 Semi-Solid Topical Formulation Market, By Country, 2010 – 2017 ($Million)
Table 42 Liquid Topical Formulation Market, By Country, 2010 – 2017 ($Million)
Table 43 Solid Topical Formulation Market, By Country, 2010 – 2017 ($Million)
Table 44 North American Implantable Drug Delivery Market, By Device, 2010 – 2017 ($Million)
Table 45 Implantable Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 46 Drug-Eluting Stents Market, By Country, 2010 – 2017 ($Million)
Table 47 Implantable Infusion Pumps Market, By Country, 2010 – 2017 ($Million)
Table 48 Contraceptive Implants Market, By Country, 2010 – 2017 ($Million)
Table 49 Intravitreal Implants Market, By Country, 2010 – 2017 ($Million)
Table 50 Brachytherapy Seeds Market, By Country, 2010 – 2017 ($Million)
Table 51 North American Transmucosal Drug Delivery Market, By Mucosa Type, 2010 – 2017 ($Million)
Table 52 North American Transmucosal Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 53 Oral Transmucosal Drug Delivery Market, By Country, 2010 – 2017 ($Million)
Table 54 Other Transmucosal Drug Delivery Technologies Market, By Country, 2010 – 2017 ($Million)
Table 55 North American Drug Delivery Market, By Country, 2010 - 2017 ($Million)
Table 56 U.S.: Drug Delivery Technologies Market, By Route Of Administration, 2010 – 2017 ($Million)
Table 57 U.S.: Oral Drug Delivery Market, By Technology, 2010 – 2017 ($Million)
Table 58 North American Pulmonary Drug Delivery Market, By Device Type, 2010 – 2017 ($Million)
Table 59 U.S.: Transdermal Drug Delivery Market, By Mode Of Delivery, 2010 – 2017 ($Million)
Table 60 U.S.: Injectable Drug Delivery Market, By Technology, 2010 – 2017 ($Million)
Table 61 U.S.: Ocular Drug Delivery Market, By Formulation, 2010 – 2017 ($Million)
Table 62 U.S.: Nasal Drug Delivery Market, By Formulation, 2010 – 2017 ($Million) 155
Table 63 U.S.: Topical Drug Delivery Market, By Formulation, 2010 – 2017 ($Million)
Table 64 U.S.: Implantable Drug Delivery Market, By Device Type, 2010 – 2017 ($Million)
Table 65 U.S.: Transmucosal Drug Delivery Market, By Mucosa Type, 2010 – 2017 ($Million)
Table 66 Canada: Drug Delivery Market, By Route Of Administration, 2010 – 2017 ($Million)
Table 67 Canada: Oral Drug Delivery Market, By Technology, 2010 – 2017 ($Million)
Table 68 Canada: Pulmonary Drug Delivery Market, By Device Type, 2010 – 2017 ($Million)
Table 69 Canada: Transdermal Drug Delivery Market, By Mode Of Delivery, 2010 – 2017 ($Million)
Table 70 Canada: Injectable Drug Delivery Market, By Technology, 2010 – 2017 ($Million)
Table 71 Canada: Ocular Drug Delivery Market, By Formulation, 2010 – 2017 ($Million)
Table 72 Canada: Nasal Drug Delivery Market, By Formulation, 2010 – 2017 ($Million)
Table 73 Canada: Topical Drug Delivery Market, By Formulation, 2010 – 2017 ($Million)
Table 74 Canada: Implantable Drug Delivery Market, By Device Type, 2010 – 2017 ($Million)
Table 75 Canada: Transmucosal Drug Delivery Market, By Mucosa Type, 2010 – 2017 ($Million)
Table 76 Mergers & Acquisitions, 2011 –2013
Table 77 Agreements, Collaborations, Joint Ventures & Partnerships, 2011 –2013
Table 78 New Product Launch, 2010 – 2012
Table 79 Other Developments, 2010 – 2013
Table 80 3M Company: Total Revenue, By Segment, 2009 – 2011 ($Million)
Table 81 3M Company: Total Revenue, By Geography, 2009 – 2011 ($Million)
Table 82 Baxter International: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 83 Baxter International: Medical Products Total Revenue, 2010 – 2012($Million)
Table 84 Baxter International: Total Revenue, By Geography, 2010 – 2012 ($Million)
Table 85 Becton, Dickinson: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 86 Becton, Dickinson: Medical Division Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 87 Becton, Dickinson: Total Revenue, By Geography, 2010 – 2012($Million)
Table 88 Catalent Pharma Solutions: Total Revenue, By Segment, 2009 – 2011 ($Million)
Table 89 Teva Pharmaceutical Industries Limited: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 90 Teva Pharmaceutical Industries Limited: Total Revenue, By Geography, 2010 – 2012 ($Million)
Table 91 Endo Health Solutions, Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 92 Johnson & Johnson, Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 93 Johnson & Johnson, Inc.: Total Revenue, By Geography, 2010 – 2012 ($Million)
Table 94 The Dow Chemical Company: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 95 Valeant Pharmaceuticals: Total Revenue, By Geography, 2010 – 2012 ($Million)

List of Figures (28 Figures)

Figure 1 North America Drug Delivery Market, By Route Of Administration (2012)
Figure 2 Drug Delivery Market Segmentation
Figure 3 Market Dynamics
Figure 4 Porter’s Five Forces Analysis For Drug Delivery Market
Figure 5 Value Chain Analysis
Figure 6 U.S. Pulmonary Drug Delivery: Market Share Analysis, By Key Player, 2012
Figure 7 Canada Pulmonary Drug Delivery: Market Share Analysis, By Key Player, 2012
Figure 8 U.S. Transdermal Drug Delivery: Market Share Analysis, By Key Player, 2012
Figure 9 Canada Transdermal Drug Delivery: Market Share Analysis, By Key Player, 2012
Figure 10 U.S. Injectable Drug Delivery Devices Market, By Key Players, 2012
Figure 11 Canada Injectable Drug Delivery Devices Market, By Key Players, 2012
Figure 12 U.S. Implantable Drug Delivery: Market Share Analysis, By Key Player, 2012
Figure 13 Canada Implantable Drug Delivery: Market Share Analysis, By Key Player, 2012
Figure 14 Opportunity Matrix: North America Drug Delivery Market (2012)
Figure 15 Oral Drug Delivery Market Share (2012)
Figure 16 Key Growth Strategies, 2010 – 2013
Figure 17 3M Company: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)
Figure 18 Aptalis Pharma, Inc.: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)
Figure 19 Baxter International: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)
Figure 20 Becton, Dickinson: Total Revenue And R&D Expenditure, 2010 – 2012 ($Million)
Figure 21 Catalent Pharma Solutions: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)
Figure 22 Teva Pharmaceutical Industries Limited: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)
Figure 23 Endo Health Solutions, Inc.: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)
Figure 24 Johnson & Johnson, Inc.: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)
Figure 25 Nektar Therapeutics, Inc.: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)
Figure 26 Psivida Corporation: Total Revenue, 2009 – 2011 ($Million)
Figure 27 The Dow Chemical Company: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)
Figure 28 Valeant Pharmaceuticals: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)

'North American Drug Delivery Technologies Market – Forecasts To 2017' covers the market for technologies used for development of products, formulations, and devices used in drug delivery. The overall market is segmented based on the oral, pulmonary, trandermal, injectable, ocular, nasal, topical, implantable, and transmucosal routes of administration used by these technologies. Oral drug delivery technologies accounted for the largest share - 38% - of the North American market in 2012, under which controlled release and orodispersible tablet technologies and other technologies such as effervescent tablets and chewable tablets are covered.

Pulmonary segment covers metered dose inhalers, dry-powder inhalers and nebulizers; this segment is growing at the highest CAGR of 11.8%. The transdermal technology market is divided into two types, namely, passive drug delivery and active drug delivery. Passive delivery is further categorized into reservoir system and matrix system, while active delivery is further categorized into iontophoresis, microporation and other technologies such as electroporation, sonophoresis and dermal ablation. Injectable technology market is classified as conventional injection, self injection, and other injection devices. Conventional devices include fillable syringes and prefilled syringes, whereas self injection devices include needle free injectors, auto-injectors, and pen injectors.

Ocular drug delivery technologies market is divided into eye drops, ophthalmic ointments, gels and other formulations like ocular inserts and punctal plugs. Based on the type of formulation, nasal drug delivery technologies market is categorized into nasal drops, sprays, and inhalers. Based on formulation type, topical drug delivery technologies market is segmented into liquid, semisolid, and solid formulations. Implantable technologies market is divided into drug eluting stents, infusion pumps, intraocular implants, brachytherapy seeds, and contraceptive implants. Transmucosal drug delivery technologies market is categorized into two segments, namely, oral transmucosal technologies (buccal and sublingual delivery) and other transmucosal technologies (rectal and vaginal formulations).

The report also covers the market by two major countries in North America, namely, the U.S and Canada. The U.S. clearly leads the market with a share of 89%, owing to the well-established pharmaceutical industries and transformations in the U.S. FDA review processes. Canada is witnessing a rise in drug approvals and partnerships related to drug delivery technologies. The increasing number of big pharma firms indulging in reformulation strategies and the rising costs of patient non-compliance in the U.S. are some of the factors that are driving the North American market. Development of home care drug delivery systems and rise in the number of therapeutic applications are some of the factors that open avenues for drug delivery market.

Key players in the market are 3M Company (U.S.), Aptalis Pharma, Inc. (U.S.), Baxter International, Inc. (U.S.), Becton Dickinson & Co. (U.S.), Catalent Pharma Solutions (U.S.), Cipher Pharmaceuticals (Canada), Dow Chemical Company (U.S.), Endo Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Nektar Therapeutics (U.S.), OptiNose (U.S.), QLT (Canada), and Valeant Pharmaceuticals (Canada).

- Aptalis Pharma, Inc
- Baxter International, Inc
- Becton, Dickinson And Company
- Catalent Pharma Solutions
- Cima Labs
- Endo Health Solutions, Inc
- Johnson & Johnson, Inc
- M Company
- Nektar Therapeutics, Inc
- Optinose As
- Psivida Corporation
- The Dow Chemical Company
- Valeant Pharmaceuticals

Note: Product cover images may vary from those shown

ALSO AVAILABLE

RELATED PRODUCTS

Our Clients

Our clients' logos